Abstract
Crisaborole, a topical phosphodiesterase-4 (PDE4) inhibitor, is effective in patients with atopic dermatitis. As systemic PDE4 inhibition has also been used with success in psoriasis, clinical trials are underway to determine the utility of topical PDE4 inhibitors in these patients. However, there is no current literature documenting use of crisaborole for psoriasis. Here, we present two cases in which patients with psoriasis were treated successfully with crisaborole.
Original language | English |
---|---|
Pages (from-to) | 156-157 |
Number of pages | 2 |
Journal | Journal of Dermatological Treatment |
Volume | 30 |
Issue number | 2 |
DOIs | |
State | Published - 17 Feb 2019 |
Keywords
- Psoriasis
- crisaborole
- phosphodiesterase-4